ERBB2 and breast cancer: The clinical significance of these findings in the context of breast cancer is that IGFBP-3 and EGFR are relatively highly expressed in some aggressive ER-negative and PR-negative tumors that lack amplification of HER2, which are now referred to as triple-negative breast cancers, or TNBC [31, 52, 53].